EXELIXIS INC (EXEL) Stock Price, Quote, News and Summary
NASDAQ:EXEL - Nasdaq - US30161Q1040 - Common Stock
EXEL Quote and Key Statistics
EXELIXIS INC
NASDAQ:EXEL (1/21/2025, 8:00:02 PM)
After market: 36.999 +0.57 (+1.56%)36.43
+0.23 (+0.64%)
EXEL Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 22.43% | ||
| ROA | 15.77% | ||
| ROE | 20.52% | ||
| Debt/Equity | 0 |
EXEL Performance and Technical Analysis
EXEL Ownership and Analysts
EXEL Latest News and Analysis
NASDAQ:EXEL appears to be flying under the radar despite its strong fundamentals.
EXELIXIS INC (NASDAQ:EXEL) is probably undervalued for the fundamentals it is displaying.
In the world of growth stocks, NASDAQ:EXEL shines as a value proposition.
NASDAQ:EXEL is showing decent growth, but is still valued reasonably.
First Week of March 21st Options Trading For Exelixis (EXEL)
BeiGene Stock Meets 80-Plus RS Rating Benchmark
One key metric to look for in a stock is an 80-plus Relative Strength Rating. BeiGene stock just hit that mark, with a jump to 84 Wednesday.
BridgeBio Pharma Stock Earns 87 RS Rating
BridgeBio Pharma stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 64 to 87.
About EXEL
Company Profile
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. The company is headquartered in Alameda, California and currently employs 1,310 full-time employees. The company went IPO on 2000-04-11. The firm is engaged in developing medicines and combination regimens at the forefront of cancer care. The company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). The firm's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.
Company Info
EXELIXIS INC
1851 Harbor Bay Parkway
Alameda CALIFORNIA 94502 US
CEO: Michael M. Morrissey
Employees: 1310
Company Website: https://www.exelixis.com/
Investor Relations: https://ir.exelixis.com
Phone: 16508377000
EXEL Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.06 | 305.03B | ||
| AMGN | AMGEN INC | 14.3 | 147.72B | ||
| GILD | GILEAD SCIENCES INC | 20.98 | 115.85B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 839 | 110.19B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.14 | 75.58B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.71B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.18B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.26B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.28B | ||
| NTRA | NATERA INC | N/A | 22.11B | ||
| BIIB | BIOGEN INC | 8.63 | 20.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.16 | 16.43B |